Creative Biostructure

Online Inquiry

Please enter "biostructure" as the verification code.

Discovery Program for Ebola Virus Targets

Discovery Program for Ebola Virus Targets

Ebola virus threatens human health since it causes deadly disease, therefore, Creative Biostructure has established an advanced Ebola virus targeted discovery platform to offer a wide variety of products and services to accelerate your structural/functional studies and novel drug/vaccine discovery.

Discovery Program for Ebola Virus Targets

What is Ebola Virus?

  • Taxonomy: filoviridae, mononegavirales;
  • Virion: filamentous, 80 x 1000 nm, enveloped;
  • Genome: approximately 19 Kb negative-sense, single-stranded RNA;
  • Proteome: 7 sequentially arranged proteins;
  • Infection: initiates by the attachment of GP glycoprotein to host receptors;
  • RNA Transcript: 5' methyl cap, 3' poly-A tail;
  • Transmission: direct contact with infected blood, organs or body fluids of infected people or animals, or objects contaminated with the virus.

Ebola Virus Proteins
Matrix protein (VP40), glycoprotein (GP), and nucleoprotein (NP) of Ebola virus play crucial role in the entry process and replication process. Its nucleoprotein composed of 738 residues, being the largest NP in negative-stranded RNA viruses. Ebola virus cannot form nucleocapsid-like structure in case of the lack of NP helix. The number 450 residue of NP is highly conserved and hydrophobic, affecting its conformation.

Therapeutic Ways against Ebola Virus
1. Antibody engineering;
The mAb in ZMapp was the first antibody found to be exposed to EBOV. This antibody was first isolated from mice, and then humanized for clinical use.
2. siRNA delivered through lipid nanoparticles;
3. Small molecule drugs with broad-spectrum antiviral properties.

Ebola Virus Products
Creative Biostructure provides various Ebola Virus products include its NP proteins, NP antibodies, and PCR kits to facilitate your scientific research.

NP Proteins EBOV (subtype Zaire) NP Protein (His Tag)
EBOV (Sudan ebolavirus, strain Gulu) NP Protein (His Tag)
EBOV (Sudan ebolavirus, strain Gulu) NP Protein 361-738 (His Tag)
NP Antibodies EBOV (subtype Zaire), NP Antibody, Rabbit PAb
PCR Kits Ebola Virus Zaire strain Single Check

Structure Determination Services of Ebola Viral Proteins

Creative Biostructure is an expert in Native Protein Purification and Mempro™ Membrane Protein Production, and our high-quality protein are especially suitable for UniCrys™ Crystallization and Structure Determination. We are able to deliver EBOV VP40, GP, and NP from gene to structure for better understanding of the pathogenic mechanism of Ebola virus.

Ebola Virus-like Particle Services
Creative Biostructure has been focused on the Ebola virus-like particles to defect the lethal Ebola virus infection because that Ebola virus remains a great global health threat since its outbreak in 2014. Our advanced Mempro™ Virus-like Particles (VLPs) Technology aims to produce custom Ebola virus-like particles containing its glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40), making them the ideal candidates to enhance vaccine research and development.

Drug Discovery against Ebola Virus
Creative Biostructure has a highly responsive team to provide comprehensive drug discovery services based on our MagHelix™ Drug Discovery technology. Creative Biostructure applies optimal strategies in order to both reduce the side effects of drugs and increase the half-life of drugs through our drug discovery process. We are specialized in utilizing high-throughput screening (HTS) for discovery of new drugs against Ebola virus and construction of large libraries of chemicals to modify the targets.

Ebola virus  targets discovery and application.
Figure 1. Ebola virus targets discovery and application.

At present, there is no approved treatment for Ebola virus infection, giving a death rate of nearly 60-90% among all diagnosed patients. Creative Biostructure has devoted to offering a comprehensive variety of research services targeting Ebola virus and established this platform to improve human health for novel vaccine/antibody discovery. Please feel free to contact us for a detailed quote.

Ordering Process

Ordering Process

References:

  1. Q. Zhang, et al. (2016). Potent neutralizing monoclonal antibodies against Ebola virus infection. Scientific Reports, 6: 25856.
  2. M. Osterholm, et al. (2016). The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Microbiology and Infectious, 16(1): e1–e9.
  3. M. Yang, et al. (2016). RT-PCR using glycoprotein target is more sensitive for the detection of Ebola virus in clinical samples. Diagnostic Microbiology and Infectious Disease, (In Press).